AYTU

Insider Trades

Name	Value	Action	Price	Current Price
Disbrow Joshua R.Chief Executive Officer $100k66.7k shares BuyJun 9, 2025 $1.50 --
Disbrow JarrettChief Business Officer $25k16.7k shares BuyJun 9, 2025 $1.50 --
Nantahala Capital Management, LLC10 Percent Owner $4004M shares BuyJun 6, 2025 $0.0001 --
Disbrow Joshua R.Chief Executive Officer $20k15k shares BuyFeb 28, 2025 $1.30 --

News

accessnewswire.comAytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026accessnewswire.comJun 1

accessnewswire.comAytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026accessnewswire.comMay 18

seekingalpha.comAytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcriptseekingalpha.comMay 13

zacks.comAytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimateszacks.comMay 13

accessnewswire.comAytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Resultsaccessnewswire.comMay 13

Trade AYTU

About Aytu BioPharma, Inc.

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

CEO: Joshua R. Disbrow
IPO Date: Sep 25, 2008

Market Data

Open: $2.13
High: $2.31
Low: $2.11
Volume: 53.6K
Avg Volume: 42.3K
52W High: $3.07
52W Low: $1.65

Valuation

Market Cap: $19M
Enterprise Value: $15M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-5.2M
Revenue: $66M
Net Income: $-14M
Cash: $31M
Debt: $23M

Events

EarningsSep 29

EPS est. -0.29